Drug Discovery@nature.com 22 June 2012

Advertisement TABLE OF CONTENTS 22 June 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement The Arab world has a rich history of scientific breakthroughs. Ensure you're part of the scientific and medical community gaining access to a regularly updated list of science jobs and local events in the Middle East. www.nature.com/nmiddleeast/ Follow us: Facebook, Twitter, & Google +   News Top Gintuit cell therapy approval signals shift at US regulator doi:10.1038/nbt0612-479 The recent approval by the US Food and Drug Administration (FDA) of a cell-based treatment for gum recession developed by Canton, Massachusetts–based Organogenesis, was the FDA's first for regenerative medicine in dental care. Full Text Pharma bankrolls academic institutes doi:10.1038/nbt0612-474a A recent wave of partnerships between pharma and academia reflects industry's need to find new ways to tap innovation. Full Text Panel proposes framework for FDA to evaluate drug risks doi:10.1038/nm0612-839b A recent proposal outlined by the US Institute of Medicine aims to bring about a more centralized and comprehensive system for drug safety monitoring. Full Text Shire drops 'emergency' Fabry's disease drug doi:10.1038/nbt0612-478c The move by Shire to withdraw its US marketing application for Replagal (agalsidase alfa) for treating the rare genetic disorder Fabry's disease has prompted surprise from industry observers and people affected by the life-threatening disorder. Full Text Analysis Top Crafting cancer combinations doi:10.1038/scibx.2012.617 Two groups have developed platforms that could improve the identification of cancer drug combinations. Full Text Pipeline pioneers: Vismodegib doi:10.1038/nrd3753 First-in-class inhibitor of the Hedgehog signalling pathway approved in the United States for the treatment of basal cell carcinoma. Full Text From the analyst's couch: Outlook for the next 5 years in drug innovation doi:10.1038/nrd3744 Analysis of industry pipeline data and revenue forecasts highlights several trends in the anticipated output of new drugs and the therapeutic area focus over the next 5 years, including a growth in the average number of new drug approvals annually. Full Text Research Highlights Top Neurological disorders: Nanoparticle opens door to cerebral palsy treatment doi:10.1038/nrd3758 Polyamidoamine dendrimers have been used to effectively deliver an anti-inflammatory drug to the brain of a rabbit model of cerebral palsy, resulting in improved motor function. Full Text Bone diseases: SEMA3A strikes a balance in bone homeostasis doi:10.1038/nrd3759 Researchers have identified semaphorin 3A as a dual regulator of osteoclasts and osteoblasts, and suggest that this could provide a strategy to address limitations of existing osteoporosis drugs that target osteoclast activity. Full Text Therapeutics: Iterations of BRAF doi:10.1038/nrc3284 Röring and colleagues investigate the involvement of the dimer interface in the ability of RAF to mediate downstream signalling, with implications for targeting BRAF. Full Text Research & Reviews Top Are sirtuins viable targets for improving healthspan and lifespan? doi:10.1038/nrd3738 This article provides an overview of the sirtuin family, focusing on sirtuin 1 and its potential to be targeted in the treatment of age-related diseases. Full Text Spatial regulation of receptor tyrosine kinases in development and cancer doi:10.1038/nrc3277 This Review discusses how dysregulation of the spatial control of receptor tyrosine kinase (RTK) activity might contribute to tumorigenesis and affect the sensitivity and resistance of cancers to pharmacological RTK inhibitors. Full Text Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing doi:10.1038/nbt.2214 Whitehead et al. demonstrate that computational design followed by comprehensive energy landscape mapping can generate proteins with potential therapeutic utility. Full Text Direct and selective small-molecule activation of proapoptotic BAX doi:10.1038/nchembio.995 A computational screen identifies a small-molecule activator of proapoptotic BAX that selectively binds to the BAX trigger site, inducing characteristic conformational changes, oligomerization and BAX-dependent cell death. Full Text Drug Discovery JOBS of the week Post-doctoral research position ("Experienced researcher still in his / her early career") "Characterization of novel nanoparticles for drug delivery to the skin" SANOFI RD Postdoctoral Researcher Marine Natural Products in Drug Discovery NUI Galway Ireland Receptor conformational modeling in presence or absence of a drug Regione Lazio - Dipartimento di Biologia Role of glycerophosphoinositols as lead for drug in rare and proliferative deseases Istituto di Biochimica delle Proteine del CNR Pre-doctoral researcher (drug resistance) Institute of Tropical Medicine (ITM) More Science jobs from Drug Discovery EVENT New Drug Product Development and Lifecycle Management 06.-07.08.12 US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.